JENNIFER SCHAEFFER: Open Payments
NPI 1821292277 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,855 in 78 payments from 14 companies in 2025. Trend: 2023 $1,014 · 2024 $1,535 · 2025 $1,855
Food & beverage: $1,801Education: $54
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $345 |
| Janssen Biotech, Inc. | 16 | $319 |
| ABBVIE INC. | 15 | $246 |
| Madrigal Pharmaceuticals | 6 | $244 |
| PFIZER INC. | 5 | $132 |
| Gilead Sciences, Inc. | 5 | $123 |
| Lilly USA, LLC | 4 | $87 |
| GENZYME CORPORATION | 2 | $69 |
| Celltrion USA Inc. | 4 | $66 |
| Phathom Pharmaceuticals, Inc. | 2 | $58 |
Products named: ENTYVIO, TREMFYA, REZDIFFRA, SKYRIZI, OMVOH, XELJANZ, DUPIXENT, VEGZELMA.
Industry payments across AZ — which companies pay providers there.
